Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Feb;69(2):394–397. doi: 10.1038/bjc.1994.73

pS2 and response to adjuvant hormone therapy in primary breast cancer.

F Spyratos 1, C Andrieu 1, K Hacène 1, P Chambon 1, M C Rio 1
PMCID: PMC1968674  PMID: 8297741

Abstract

We reviewed 319 primary breast tumours for cytosolic pS2 content, with a median follow-up of 6 years. pS2 status correlated positively with oestradiol and progesterone receptors and negatively with Scarff, Bloom and Richardson grade. pS2 positivity was associated with longer overall survival, particularly in patients who received hormone therapy, in whom pS2 status was also predictive of the response to therapy.

Full text

PDF
394

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BLOOM H. J., RICHARDSON W. W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957 Sep;11(3):359–377. doi: 10.1038/bjc.1957.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Berry M., Nunez A. M., Chambon P. Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence. Proc Natl Acad Sci U S A. 1989 Feb;86(4):1218–1222. doi: 10.1073/pnas.86.4.1218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Foekens J. A., Rio M. C., Seguin P., van Putten W. L., Fauque J., Nap M., Klijn J. G., Chambon P. Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res. 1990 Jul 1;50(13):3832–3837. [PubMed] [Google Scholar]
  4. Foekens J. A., van Putten W. L., Portengen H., de Koning H. Y., Thirion B., Alexieva-Figusch J., Klijn J. G. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. J Clin Oncol. 1993 May;11(5):899–908. doi: 10.1200/JCO.1993.11.5.899. [DOI] [PubMed] [Google Scholar]
  5. Goussard J., Lechevrel C., Roussel G., Cren H., Bera O., Sala M. Immunoradiometric assay of pS2 protein in breast cancer cytosols. Clin Chem. 1991 Oct;37(10 Pt 1):1759–1762. [PubMed] [Google Scholar]
  6. Henry J. A., Piggott N. H., Mallick U. K., Nicholson S., Farndon J. R., Westley B. R., May F. E. pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. Br J Cancer. 1991 Apr;63(4):615–622. doi: 10.1038/bjc.1991.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Horwitz K. B., McGuire W. L. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science. 1975 Aug 29;189(4204):726–727. doi: 10.1126/science.168640. [DOI] [PubMed] [Google Scholar]
  8. Jensen E. V., Greene G. L., Closs L. E., DeSombre E. R., Nadji M. Receptors reconsidered: a 20-year perspective. Recent Prog Horm Res. 1982;38:1–40. doi: 10.1016/b978-0-12-571138-8.50006-8. [DOI] [PubMed] [Google Scholar]
  9. Klijn J. G., Berns P. M., Bontenbal M., Alexieva-Figusch J., Foekens J. A. Clinical breast cancer, new developments in selection and endocrine treatment of patients. J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):211–221. doi: 10.1016/0960-0760(92)90210-a. [DOI] [PubMed] [Google Scholar]
  10. Koerner F. C., Goldberg D. E., Edgerton S. M., Schwartz L. H. pS2 protein and steroid hormone receptors in invasive breast carcinomas. Int J Cancer. 1992 Sep 9;52(2):183–188. doi: 10.1002/ijc.2910520205. [DOI] [PubMed] [Google Scholar]
  11. Masiakowski P., Breathnach R., Bloch J., Gannon F., Krust A., Chambon P. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res. 1982 Dec 20;10(24):7895–7903. doi: 10.1093/nar/10.24.7895. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Predine J., Spyratos F., Prud'homme J. F., Andrieu C., Hacene K., Brunet M., Pallud C., Milgrom E. Enzyme-linked immunosorbent assay of pS2 in breast cancers, benign tumors, and normal breast tissues. Correlation with prognosis and adjuvant hormone therapy. Cancer. 1992 Apr 15;69(8):2116–2123. doi: 10.1002/1097-0142(19920415)69:8<2116::aid-cncr2820690818>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  13. Rio M. C., Bellocq J. P., Gairard B., Rasmussen U. B., Krust A., Koehl C., Calderoli H., Schiff V., Renaud R., Chambon P. Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2. Proc Natl Acad Sci U S A. 1987 Dec;84(24):9243–9247. doi: 10.1073/pnas.84.24.9243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Schwartz L. H., Koerner F. C., Edgerton S. M., Sawicka J. M., Rio M. C., Bellocq J. P., Chambon P., Thor A. D. pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res. 1991 Jan 15;51(2):624–628. [PubMed] [Google Scholar]
  15. Thompson A. M., Hawkins R. A., Elton R. A., Steel C. M., Chetty U., Carter D. C. pS2 is an independent factor of good prognosis in primary breast cancer. Br J Cancer. 1993 Jul;68(1):93–96. doi: 10.1038/bjc.1993.292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Thor A. D., Koerner F. C., Edgerton S. M., Wood W. C., Stracher M. A., Schwartz L. H. pS2 expression in primary breast carcinomas: relationship to clinical and histological features and survival. Breast Cancer Res Treat. 1992;21(2):111–119. doi: 10.1007/BF01836957. [DOI] [PubMed] [Google Scholar]
  17. Wysocki S. J., Hahnel E., Wilkinson S. P., Smith V., Hahnel R. Hormone-sensitive gene expression in breast tumours. Anticancer Res. 1990 Jan-Feb;10(1):185–188. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES